INTRODUCTION
Metabolic enzymes of the UDP-glucuronosyltransferase (UGT) superfamily catalyze glucuronidation reactions involved in the disposition of endogenous molecules, drugs and other xenobiotics. UGTs are glycoproteins resident of the endoplasmic reticulum (ER) membranes that undergo post-translational modifications (PTM) such as glycosylation and phosphorylation (Mackenzie 1990 , Chakraborty et al. 2012 , Riches and Collier 2015 . This family of proteins are involved in drug metabolism, accounting for approximately 55% of the 200 most prescribed drugs (Guillemette et al. 2014) . UGT2B7 is of particular interest as it is the most prevalent member of this enzyme family, conjugates almost one fifth of all drugs known to be conjugated to glucuronic acid (Stingl et al. 2014) . For instance, UGT2B7 is involved in the inactivation and elimination of carboxylic acid-containing drugs including the nonsteroidal anti-inflammatory drugs (NSAIDs), and of a large variety of other drugs including opioids, the anticonvulsant valproic acid, morphine, codeine, efavirenz, fenofibric acid, mycophenolic acid (MPA) and zidovudine (AZT) (Stingl et al. 2014) .
Glucuronide formation varies greatly between individuals and may be explained in part by the presence of single nucleotide polymorphisms (SNPs) (Guillemette et al. 2014 ). In the case of UGT2B7, there is a well-established connection to variation in drug efficacy and toxicity, especially for the most common polymorphism UGT2B7*2 allele that encodes a nonconservative amino acid substitution His 268 Tyr in the substrate-binding domain linked to altered pharmacokinetics of several drugs but not all substrates examined (Bhasker et al. 2000 , Stingl et al. 2014 . Most pharmacogenomics studies currently survey common variants and thus are only observing a small fraction of the genetic diversity in any gene. Different forms of genetic variations within a UGT locus, including common and rare coding and regulatory variants, can exist and have separate and yet cumulative effects. Rare variants (allele frequency <1%) may also cause interindividual differences in therapeutic effects and adverse reactions to drugs but have been much less studied (Nelson et al. 2012) . This is highly relevant since rare variants are predicted to greatly outnumber common variants in the human genome (Marth et al. 2011 ) and they may be very important in the genomic contribution to treatment response and toxicity (Ramsey et al. 2012 , Gillis et al. 2014 . For example, it was recently established that as much as 92% of known variants in the cytochrome P450 superfamily have an allelic frequency below 1%, and 83% below 0.1% (Fujikura et al. 2015) . Similar distribution of variants by allelic frequency might be observed in UGT2B7 and other UGTs, underscoring the importance of studying rare variants.
Here we report the identification of a novel rare missense UGT2B7 variant (NM_001074.2:c.361G>A) in a Caucasian cohort of 305 healthy volunteers. This rare variation leads to the translation of an asparagine (Asn) instead of an aspartic acid (Asp) at position 121 of the UGT2B7 protein (NP_001065.2:p.Asp121Asn; D 121 N). Investigation of its functional impact using bioinformatics tools predicted that this variation creates a putative N-glycosylation site, which was experimentally validated. We then studied whether this additional PTM site affects glucuronidation of AZT and MPA, demonstrating a drastic reduction in UGT2B7 catalytic activity. Lastly, we established a comprehensive dataset of 32 rare variants potentially affecting gain or loss of N-glycosylation sites in other family members, with some located in regions highly conserved across UGT genes, by integrating data from the dbSNP database along with their respective allelic frequency. Collectively, these low-frequency variants have the potential to increase the proportion of variance explained in the glucuronidation pathway. DMD #071860 6
MATERIALS AND METHODS

Genotyping of healthy Caucasian volunteers. The variation at position 361 in the UGT2B7
gene causing amino acid change Asp 121 Asn was initially observed in one of 52 participants of a previous pharmacokinetic study , Levesque et al. 2008 ). These healthy volunteers were selected in a population of 305 Caucasian subjects that were subsequently genotyped for the variation at codon 121 using specific primers, as described , Levesque et al. 2008 , and a second subject was found to carry this variation.
Heterologous expression of the variant UGT2B7 enzyme and enzymatic assays. A HEK293
cell line expressing the variant UGT2B7 protein at codon 121 (UGT2B7Asn 121 ) was established by mutagenesis using primers 5'-CCCAACAACTCATCCTCTCTTAAAATTGAAA-3' (forward) and 5'-TTTCAATTTTAAGAGAGGATGAGTTGTTGGG-3' (reverse) based on the reference UGT2B7 cDNA (Menard et al. 2011) . Relative quantification of UGT protein content in microsomal proteins was performed by immunoblot analysis using an anti-UGT2B antibody EL-93 (dilution 1:2000) (Lepine et al. 2004 ) and with an anti-calnexin antibody (dilution 1:5000;
Stressgen Biotechnologies, Victoria, Canada) to normalize for sample loading. Kinetic parameters were assessed for both cell lines in the presence of increasing concentrations of substrates, MPA (25 to 1500 µM; MP Biomedicals, Santa Ana, CA) or AZT (100 to 5000 µM;
Sigma-Aldrich, St. Louis, MO) and fixed UDPGA (5 mM), or co-substrate UDPGA (from Sigma-Aldrich, St. Louis, MO) (50 to 5000 µM; fixed AZT (500 µM or 1 mM)), for 1-hour incubation at 37°C. Enzymatic assays and liquid chromatography-mass spectrometry were performed to assess glucuronide (G) formation as described ).
Absolute velocities (V max : pmol/min/mg protein) were normalized for UGT protein content assessed by western blotting and expressed as relative V max (pmol/min/mg protein/UGT content). were harvested 24h/40h post-transfection by washing twice in PBS then homogenates were prepared by harvesting cells in phosphate-buffered saline containing 0.5 mM DTT. To control for ER stress, cells were transfected as above, thapsigargin (0.5 µM; Sigma-Aldrich) was added at time of transfection and cells were harvested 24 h post-treatment as above. Protein concentration in homogenates was determined by a bicinchoninic acid assay. Immunodetection of UGT2B7 was as described above.
Analysis of UGT2B genetic variations.
Single nucleotide variations (SNPs) for UGT2B coding sequences were retrieved from the dbSNP database using the NCBI browser (U.S. National Library of Medecine, Bethesda, MD). Alignments of UGT2Bs were obtained using the Clustal O (1.2.1) multiple sequence alignment tool. Coding variations were analyzed to establish whether they affect the sequence context Asn-X-Ser/Thr (create or disrupt NX(S/T) motif), where X is any amino acid except proline.
RESULTS AND DISCUSSION
Our analysis of UGT2B7 gene sequences in a population of 305 healthy volunteers uncovered a novel missense variation observed in two individuals and corresponding to a nonsynonymous coding variation at codon 121 (Asp 121 Asn). A Sanger sequencing chromatogram is presented in Fig.1A designating a double peak of an adenine (A) and a guanine (G) at position 361 (allelic frequency of 0.328% for the variant A allele). This population was previously used to identify candidates carrying specific UGT1A and UGT2B7 genetic variations for a pharmacokinetic study of mycophenolate mofetyl , Levesque et al. 2008 ). An in silico analysis for prediction of PTM sites using the NetNGlyc 1.0 tool (http://www.cbs.dtu.dk/services/NetNGlyc/) also confirmed with the GlycoEP software (Chauhan et al. 2013) , revealed that this amino acid change creates a putative asparagine-linked N-glycosylation motif NX(S/T) consisting of an asparagine followed 2 positions downstream by a threonine as pictured in Fig.1D . Three such motifs are typically found in the UGT2B7 protein, of which glycosylation at positions 68 and 315 was experimentally validated (Nagaoka et al. 2012 ). The western blot analysis of HEK293 microsomal preparations showed that the variant UGT2B7Asn 121 protein has a higher molecular weight than the UGT2B7Asp 121 enzyme, which is consistent with the addition of an oligosaccharide by N-glycosylation. In contrast to Oglycosidase treatment, when treated with Endo H, oligosaccharides are removed leaving both UGT2B7 proteins at the same lower molecular weight, thus confirming the presence of an additional N-glycosylation on the variant UGT2B7Asn 121 protein (Fig.1B) . As further evidence of N-glycosylation causing the enhanced mobility shift of the UGT2B7Asn 121 protein, Nglycosylation of endogenously produced UGT2B7 was inhibited with tunicamycin (Nakajima et al. 2010 ). Both the reference and variant UGT2B7 were detected as multiple protein bands with low drug concentration, suggesting a partially perturbed glycosylation, whereas the high drug concentration prevented the formation of slower migrating proteins, thus confirming that the mobility shift is caused by N-glycosylation (Fig.1C) . Inhibition was not due to a general ER stress impairing glycosylation, given that thapsigargin did not perturb the mobility of either UGT2B7 (Fig.1C) We also used mass spectrometry analysis with the goal to detect the glycosylated peptide containing the sequence at codon 121. This approach, using cellular fractions from HEK293-UGT2B7 cell models enriched for UGT2B7 by affinity purification and treated or not with endoglycosidase PNGase F, was inconclusive. It permitted the detection of multiple UGT2B7 tryptic peptides (protein coverage up to 29%; data not shown) but not the codon 121-bearing peptide.
Previous data support that N-glycosylation plays a significant role in the enzymatic activity of UGT2B7 (Barbier et al. 2000 , Nagaoka et al. 2012 ), suggesting that the novel UGT2B7Asn 121 variat may affect enzyme activity. A significant alteration in the conjugation of AZT and MPA was observed, with a decreased activity by 49% and 40%, respectively, associated with the variant Asn 121 protein compared to the reference Asp 121 enzyme, suggesting an altered protein folding. No significant differences were noted in the affinity (K m ) of the enzyme (Table 1,   Fig.1E ). Nagaoka and colleagues showed that disruption of N-glycosylation sites at position 68 and 315 by mutagenesis leads to significant changes in the activity of the UGT2B7 enzyme (Nagaoka et al. 2012) . Similarly, abolition of the N-glycosylation of UGT2B15 resulted in decreased enzyme activity without changing K m (Barbier et al. 2000) . In line, a rare UGT1A1 variant creating a glycosylation site (K 402 T) was reported to cause a drastic decrease in UGT activity associated with severe hyperbilirubinemia (Crigler-Najjar type 1) (Sneitz et al. 2010) .
These observations underscore the need for further research on the impact of the N-glyco variants on UGT2B7 protein function as well as on other UGTs.
Our goal was next to build a framework for better understanding the effects of non-synonymous variations on the N-glycosylation of UGT2B enzymes. Through a systematic survey of publicly available data (dbSNP database), we revealed numerous naturally occurring missense variations, most with low allelic frequency (below 0.01%), predicted to affect N-glycosylation of UGT2B enzymes (Table 2, Fig.1F ). Very little information is still available regarding the glycosylation profile of UGT enzymes, precluding us from establishing the potential functional relevance of these rare variants. Clustering of the variants according to their position in the UGT sequences helped visualize the fact that many of them localize in the same regions of UGT1, UGT2A or UGT2B enzymes. These potentially correspond to conserved and functional NX(S/T) motifs across several UGT proteins (Fig.1F) , hence making them interesting candidates for further in vitro validation. For example, the first cluster is noteworthy because N-glycosylation in this region of UGT2B7 and UGT2B15, on residues 68 and 65 respectively, was experimentally validated in liver tissue by a method combining multiple digestion and hydrazide chemistry (Chen et al. 2009 ). Likewise, codon 69 of UGT2B4, UGT2B11 and UGT2B28 is affected by naturally occurring rare variants creating at this position the final serine or threonine of an NX(S/T) glycosylation motif, whereas a similar motif is present in this region for UGT1A and UGT2A enzymes. A comprehensive survey of the impact of these additional rare variants on the N-glycosylation of UGT enzymes will be required to evaluate if variations that lead to changes in the glycosylation pattern of a UGT protein can be damaging.
In conclusion, we discovered a rare UGT2B7 
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